Interferon-β-1a (Avonex) 30 mcg and 60 mcg are equally effective in patients with relapsing multiple sclerosis:: results from the Cyprus study site of the European IFNβ-1a Dose Comparison Study

被引：0
作者：
Kkolou, E [1 ]
Papacostas, S [1 ]
Kyriallis, K [1 ]
Toufexis, J [1 ]
Pantzaris, M [1 ]
机构：
[1] Cyprus Inst Neurol & Genet, Nicosia, Cyprus
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
[41]   Sustained efficacy of interferon beta-1a in relapsing multiple sclerosis: Four-year results from the European Dose-Comparison Study [J].
Kappos, L ;
Clanet, M .
NEUROLOGY, 2002, 58 (07) :A460-A460
[42]   Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II) [J].
Francesco Patti ;
Maria Pia Amato ;
Maria Trojano ;
Stefano Bastianello ;
Maria Rosalia Tola ;
Orietta Picconi ;
Sabina Cilia ;
Salvatore Cottone ;
Luigi M. E. Grimaldi .
Quality of Life Research, 2012, 21 :1111-1121
[43]   A randomized comparative study of antibody development to IFN-β1A and IFN-β1B in patients with multiple sclerosis [J].
Ross, C ;
Svenson, M ;
Koch-Henriksen, N ;
Soelberg-Sorensen, P ;
Skovgaard, GL ;
Bendtzen, K .
EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) :502-502
[44]   Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study [J].
Spyros N. Deftereos ;
Evangelos Koutlas ;
Efrosini Koutsouraki ;
Athanassios Kyritsis ;
Panagiotis Papathanassopoulos ;
Nikolaos Fakas ;
Vaia Tsimourtou ;
Nikolaos Vlaikidis ;
Antonios Tavernarakis ;
Konstantinos Voumvourakis ;
Michalis Arvanitis ;
Dimitrios Sakellariou ;
Filippo DeLorenzo .
BMC Neurology, 18
[45]   Magnetic resonance imaging results of the PRISMS trial:: A randomized, double-blind, placeblo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis [J].
Li, DKB ;
Paty, DW .
ANNALS OF NEUROLOGY, 1999, 46 (02) :197-206
[46]   Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis:: three-year data from the OWIMS study [J].
Freedman, MS ;
Francis, GS ;
Sanders, EACM ;
Rice, GPA ;
O'Connor, P ;
Comi, G ;
Duquette, P ;
Metz, L ;
Murray, TJ ;
Bouchard, JP ;
Abramsky, O ;
Pelletier, J ;
O'Brien, F .
MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (01) :41-45
[47]   Subcutaneous Interferon β-1a in Children and Adolescents with Multiple Sclerosis: An International Retrospective Study of 307 Patients [J].
Pohl, Daniela ;
Banwell, Brenda ;
Ghezzi, Angelo ;
Krupp, Lauren ;
Boyko, Alexey ;
Meinel, Michel ;
Rocak, Sanda ;
Moraga, Margot Stam ;
Tenembaum, Silvia .
NEUROLOGY, 2012, 78
[48]   Treatment de-escalation after mitoxantrone therapy: design and baseline data of a phase IV, multicentre, open-label, randomised study of subcutaneous interferon β-1a (44mcg tiw) in patients with relapsing multiple sclerosis (the REMAIN study) [J].
Gold, R. ;
Heidenreich, F. ;
Rieckmann, P. ;
Sailer, M. ;
Zettl, U. K. ;
Zessack, N. .
MULTIPLE SCLEROSIS, 2009, 15 (09) :S252-S253
[49]   CSF kappa light chains and gadolinium-enhancing brain lesions as predictors of response to therapy with interferon beta 1a (Avonex®) in patients with relapsing multiple sclerosis [J].
Rudick, R ;
Cookfair, D ;
Simon, J ;
Simonian, N ;
Jacobs, L ;
Herndon, R ;
Richert, J ;
Salazar, A ;
Fischer, J ;
Granger, C ;
Goodkin, D ;
O'Reilly, K ;
Boyle, S .
NEUROLOGY, 1998, 50 (04) :A342-A342
[50]   Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study [J].
Lanzillo, R. ;
Quarantelli, M. ;
Bonavita, S. ;
Ventrella, G. ;
Lus, G. ;
Vacca, G. ;
Prinster, A. ;
Orefice, G. ;
Tedeschi, G. ;
Morra, V. Brescia .
ACTA NEUROLOGICA SCANDINAVICA, 2012, 126 (05) :306-314
12345